ALK and inflammatory myofibroblastic tumor: No clinical trials for systemic treatment have focused solely on IMTs, but a recent phase I trial for refractory pediatric solid tumors demonstrated three of seven ALK-rearranged IMT patients had partial responses, and another three had stable disease on crizotinib treatment [21].